Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00155
2008-02-15
Prospective
Not applicable
N/A
Nil
Nil
Ms. Joyce Kung
UEC, 3/F, Hong Kong Eye Hospital, 147K Argyle Street
27623134
joycekung@cuhk.edu.hk
Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong
Prof. Dennis SC Lam
3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon.
27623134
email dennislam_cu_res@cuhk.edu.hk
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Post phacoemulsification cystoid macular edema: Incidence, risk factors and efficacy of non-steroidal anti-inflammatory drug in its prevention
Post phacoemulsification cystoid macular edema: Incidence, risk factors and efficacy of non-steroidal anti-inflammatory drug in its prevention
Not applicable
Hong Kong
Yes
2007-11-10
phacoemulsification cystoid macular edema
Drug
Topical NSAID (ketorolac)
4 weeks after cataract surgery
Study group will receive ketorolac tromethamine 0.5% (Acular) eye drop Control group will receive placebo ie. 0.9%normal saline eye drop
Inclusion criteria 1. Senile cataract in patients older than 50 years old 2. Adequate fundal view for OCT measurement before cataract surgery 3. pre-op OCT could be obtained with signal strength 6.0 4. fully informed consent
Exclusion criteria 1. pre-existing macular edema 2. any conditions known to cause macular edema, including retinal vein or artery occlusion, uveitis, premacular fibrosis, retinitis pigmentosa, macular hole and choroidal neovascularisation 3. significant ocular diseases such as glaucoma 4. pre-existing refractive error of >-6.00 diopters or +6.00 diopters 5. systemic medications that may affect retinal thickening such as steroid or diuretics 6. single eye patients 7. For diabetic patients, history of intravitreal or sub-Tenon¡¦s capsule injection or triamcinolone acetonide.
51
None set
Both Male and Female
Interventional
Randomized
Placebo
Double-blind
Parallel
2009-12-01
200
Complete
1. Macular thickness and central foveal volume assessed by OCT
2. Best corrected visual acuity (ETDRS chart) 3. risk factors for development of CME ( e.g. phaco time, phaco energy etc.) 4. development of posterior vitreous detachment
2012-04-17
ChiCTR-TRC-09000713
2010-05-04
Yes
Nil
|
|
|
|
|
---|---|---|---|---|
No documents yet. |